Trials / Completed
CompletedNCT06565975
Characteristics and Outcomes of Acute Myeloid Leukemia (AML) Patients Treated With Oral-Azacitidine Maintenance Therapy in France
RELION Study: Characteristics and Outcomes of the Patient Population With Acute Myeloid Leukemia in Remission, Treated With Oral Azacitidine Maintenance in France
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 112 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to collect and evaluate real-world data to describe the outcomes, patient characteristics, safety profile and treatment patterns of oral azacitidine prescribed as maintenance treatment after frontline treatment or second remission for acute myeloid leukemia in France.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Oral azacitidine | As per product label, prescribed by treating physician |
Timeline
- Start date
- 2023-05-23
- Primary completion
- 2026-01-26
- Completion
- 2026-01-26
- First posted
- 2024-08-22
- Last updated
- 2026-02-12
Locations
1 site across 1 country: France
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06565975. Inclusion in this directory is not an endorsement.